VEA
ABUS icon

Virtus ETF Advisers’s Arbutus Biopharma ABUS Stock Holding History

Virtus ETF Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,970
Closed -$65.3K – 421
2024
Q4 		$65.3K Sell
19,970
-9,192
-32% -$33.8K 0.03% 418
2024
Q3 		$112K Buy
29,162
+515
+2% +$1.98K 0.05% 359
2024
Q2 		$88.5K Buy
+28,647
New +$85.9K 0.04% 366
2023
Q4 		– Sell
-40,040
Closed -$81.3K – 426
2023
Q3 		$81.3K Sell
40,040
-3,984
-9% -$8.35K 0.05% 358
2023
Q2 		$101K Buy
44,024
+6,827
+18% +$17.8K 0.06% 374
2023
Q1 		$113K Sell
37,197
-14,299
-28% -$40.3K 0.06% 329
2022
Q4 		$120K Buy
51,496
+8,508
+20% +$20.4K 0.06% 416
2022
Q3 		$82K Buy
42,988
+313
+0.7% +$737 0.03% 427
2022
Q2 		$116K Buy
42,675
+5,227
+14% +$13.4K 0.04% 394
2022
Q1 		$112K Sell
37,448
-2,227
-6% -$6.82K 0.05% 283
2021
Q4 		$154K Buy
+39,675
New +$154K 0.06% 340
2016
Q2 		– Sell
-54,471
Closed -$225K – 148
2016
Q1 		$225K Buy
+54,471
New +$195K 0.31% 71

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
FC
Foursixthree Capital New York $485M AUM 117.01% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.19B AUM 63.92% 1-Year Est. Return

Virtus ETF Advisers's ABUS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 19,970 shares — an estimated $65.3K sold.

Virtus ETF Advisers first reported a position in ABUS in Q1 2016 and held it in 12 quarters. The position peaked at $225K in Q1 2016. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 19,970 Arbutus Biopharma shares in Q1 2025, an estimated $65.3K.
  • Virtus ETF Advisers first reported a position in Arbutus Biopharma in Q1 2016 and held it in 12 quarters.
  • Virtus ETF Advisers's Arbutus Biopharma position peaked at $225K in Q1 2016.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.